Pull to refresh
Logo
Daily Brief
Following
Why Ranks Sign Up
Hansoh Pharmaceutical Group

Hansoh Pharmaceutical Group

Pharmaceutical company

Appears in 1 story

Stories

Hansoh's B7-H3 ADC wins China breakthrough status for esophageal cancer

New Capabilities

Developer of HS-20093, the lead B7-H3 ADC in China

Patients with advanced esophageal squamous cell carcinoma who fail both chemotherapy and immunotherapy have almost no good options. On May 11, China's drug regulator granted breakthrough status to Hansoh Pharmaceutical's HS-20093, a targeted cancer drug built around a protein called B7-H3.

Updated 5 days ago